uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
April 24 2017 - 4:05PM
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that five abstracts have been accepted for
presentation at the American Society of Gene and Cell Therapy
(ASGCT) 20th Annual Meeting held in Washington, D.C., May 10-13,
2017. Together with their collaborators, members of uniQure’s
research and development team will present data focused on progress
in re-administration protocols, gene therapy delivery systems and
optimized vector distribution technologies in two of uniQure’s key
programs, hemophilia B and Huntington’s disease. An investor and
analyst breakfast meeting featuring senior members of uniQure’s
research and development team will be held on Friday, May 12 at 7
a.m.
“The data to be presented at the ASGCT meeting
demonstrate the development and validation of uniQure’s
technologies to improve gene therapy as a therapeutic approach, and
supports our aim to rapidly bring new disease-modifying therapies
to patients with severe genetic diseases,” stated Matthew Kapusta,
chief executive officer of uniQure.
Harald Petry, Ph.D., chief scientific officer at
uniQure, added, “We are making strong progress in advancing the
preclinical development of AMT-130 in Huntington’s disease, and
further enhancing AAV vector technology and the potential for
re-administration protocols, which continue to provide compelling
evidence of our modular platform.”
Specific details on uniQure’s presentations at
ASGCT include:
- Title: Novel AAV Vector Reservoirs: peripheral
Blood Cells and Hematopoietic Progenitors. (collaborator
presentation)Oral Session Title: AAV Vector
BiologyDate and Time: Wednesday, May 10, 2017,
10:30 a.m. EDTLocation: Marriott Salon 1
- Title: Circulating Anti-AAV5 Neutralizing
Antibody Titers up to 1:1031 Do Not Affect Liver Transduction
Efficacy of AAV5 Vectors in Non-Human Primates (Poster
198).Poster Session Title: Immunological Aspects
of Gene Therapy and Vaccines ISession Date and
Time: Wednesday, May 10, 2017, 5:30 – 7:30 p.m.
EDTLocation: Hall A&B South
- Title: Successful Repeated Hepatic Gene
Delivery in Non-Human Primates Achieved with AAV5 by Use of Immune
Adsorption (Poster 395).Poster Session Title:
Immunological Aspects of Gene Therapy and Vaccines
IISession Date and Time: Thursday, May 11, 2017,
5:15 – 7:15 p.m. EDTLocation: Hall A&B
South
- Title: AAV5-miHTT Gene Therapy Demonstrates
Broad Vector Distribution and Strong Mutant Huntingtin Lowering in
a Huntington’s Disease Minipig Model.Oral Session
Title: Preclinical Progress Towards Therapies for
Neurologic DisordersDate and Time: Friday, May 12,
2017, 4:30 p.m. EDTLocation: Delaware AB
- Title: Detection of AAV Vector DNA and
Transgene RNA in Liver Tissue by Fluorescent In Situ Hybridization
(Poster 567).Poster Session Title: AAV Vectors
IIISession Date and Time: Friday, May 12, 2017,
5:45 – 7:45 p.m. EDTLocation: Hall A&B
South
Investor and Analyst
BreakfastuniQure management will host an investor and
analyst breakfast meeting featuring members of the research and
development team to review the data presented during ASGCT.
Date and
Time: |
|
Friday, May 12, 2017 at
7:00 am EDT |
Location: |
|
Omni Shoreham Hotel,
The Congressional Room, 2500 Calvert Street NW, Washington,
DC. |
|
|
The Omni Shoreham hotel
is located directly across the conference venue. |
To request attendance at the meeting, please
RSVP to Investors@uniQure.com by May 5, 2017, as space is
limited.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
liver/metabolic, central nervous system and cardiovascular
diseases. www.uniQure.com
uniQure Forward-Looking Statements This press
release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements,
which are often indicated by terms such as "anticipate," "believe,"
"could," "estimate," "expect," "goal," "intend," "look forward to",
"may," "plan," "potential," "predict," "project," "should," "will,"
"would" and similar expressions. Forward-looking statements are
based on management's beliefs and assumptions and on information
available to management only as of the date of this press release.
These forward-looking statements include, but are not limited to,
statements regarding the development of our gene therapy
product candidates. Our actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with
collaboration arrangements, our and our collaborators' clinical
development activities, regulatory oversight, product
commercialization and intellectual property claims, as well as the
risks, uncertainties and other factors described under the heading
"Risk Factors" in uniQure's 2016 Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 15, 2017.
Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements,
even if new information becomes available in the future.
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024